42476-63-1

Usage

Uses

Used in Pharmaceutical Industry:
O-(2-Morpholin-4-yl-ethyl)-hydroxylaMine is used as a building block for the synthesis of various organic compounds, particularly in the development of pharmaceuticals. Its ability to act as a nitroxyl donor makes it a valuable component in drug development, contributing to the creation of new therapeutic agents.
Used in Agricultural Industry:
Similarly, in the agricultural sector, O-(2-Morpholin-4-yl-ethyl)-hydroxylaMine serves as a key component in the synthesis of agrochemicals. Its role in creating effective and targeted compounds aids in enhancing crop protection and management strategies.
Used in Specialty Chemicals Production:
O-(2-Morpholin-4-yl-ethyl)-hydroxylaMine is also utilized in the production of specialty chemicals, where its unique structure and properties allow for the development of customized chemical solutions for specific applications.
Used in Synthesis of Heterocyclic Compounds:
Furthermore, O-(2-Morpholin-4-yl-ethyl)-hydroxylaMine has potential applications in the synthesis of various heterocyclic compounds, which are important in numerous areas of chemistry, including the creation of new pharmaceuticals, dyes, and other specialty chemicals.
Safety Note:
It is important to handle O-(2-Morpholin-4-yl-ethyl)-hydroxylaMine with care, as it can be hazardous if not used properly. Proper safety measures and handling protocols should be followed to ensure the safe use of this chemical compound in research and industrial applications.

Upstream product

• 6514-43-8 (2-morpholin-4-yl-ethoxy)-carbamic acid ethyl ester 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 

Downstream Products

• 1170232-13-9 tert-butyl 8-(benzyl(2-morpholinoethoxy)amino)-8-oxooctylcarbamate 
• 1170232-17-3 tert-butyl 6-(benzyl(2-morpholinoethoxy)amino)-6-oxohexylcarbamate 
• 1170236-58-4 N-benzyl-8-(2-cyano-3-(pyridin-4-yl)guanidino)-N-(2-morpholinoethoxy)-octanamide 
• 1170232-14-0 8-amino-N-benzyl-N-(2-morpholinoethoxy)octanamide 
• 1202571-67-2 N-benzyl-7-(3,4-dioxo-2-(pyridin-4-ylamino)cyclobut-1-enylamino)-N-(2-morpholinoethoxy)heptanamide 
• 1170231-26-1 N-benzyl-O-(2-morpholinoethyl)hydroxylamine 
• 1170233-35-8 N-cyclobutyl-O-(2-morpholinoethyl)hydroxylamine 
• 1178540-65-2 (R,Z)-2-amino-7-(2-bromo-4-fluorophenyl)-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one O-2-morpholinoethyloxime 
• 76852-48-7 1-(4-Chloro-phenyl)-7-dimethylamino-heptan-1-one O-(2-morpholin-4-yl-ethyl)-oxime 

Relevant academic research and scientific papers

Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship

Existing pharmacological inhibitors for nicotinamide phosphoribosyltransferase (NAMPT) are promising therapeutics for treating cancer. By using medicinal and computational chemistry methods, the structure-activity relationship for novel classes of NAMPT inhibitors is described, and the compounds are optimized. Compounds are designed inspired by the NAMPT inhibitor APO866 and cyanoguanidine inhibitor scaffolds. In comparison with recently published derivatives, the new analogues exhibit an equally potent antiproliferative activity in vitro and comparable activity in vivo. The best performing compounds from these series showed subnanomolar antiproliferative activity toward a series of cancer cell lines (compound 15: IC50 0.025 and 0.33 nM, in A2780 (ovarian carcinoma) and MCF-7 (breast), respectively) and potent antitumor in vivo activity in well-tolerated doses in a xenograft model. In an A2780 xenograft mouse model with large tumors (500 mm3), compound 15 reduced the tumor volume to one-fifth of the starting volume at a dose of 3 mg/kg administered ip, bid, days 1-9. Thus, compounds found in this study compared favorably with compounds already in the clinic and warrant further investigation as promising lead molecules for the inhibition of NAMPT.

OXIM DERIVATIVES AS HSP90 INHIBITORS

The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

VERSIPELOSTATIN DERIVATIVE, ANTI-CANCER AGENT AND PROCESSES FOR PRODUCTION OF THE DERIVATIVE AND AGENT

Provided is a new anti-cancer agent lower in cell toxicity. The present invention provides the compounds represented by the general formula of "Formula 1" or the salt thereof. The compounds are compounds having an organic group introduced on a particular ketone group of VST that functions to inhibit induction of GRP 78 expression, similarly to VST, and is applicable, for example, as an anti-cancer agent. The compounds are also advantageous in that it is less toxic than VST and has lower adverse reaction.

3-aryl-7-chloro-3,4-dihydroacridine-1,9(2H,10H)-dione 1-oximes and 1-hydrazone derivatives, their salts, a process for their preparation, agents containing them and their use

3-Aryl-7-chloro-3,4-dihydroacridine-1,9(2H,10H)-dione 1-oximes and 1-hydrazone derivatives of the formula I STR1 and their physiologically tolerated acid addition and ammonium salts are described, as is a process for their preparation. The new compounds are chemotherapeutic agents and are active against protozoa, especially malaria plasmodia.